Moleculin Announces $5.9 Million Public Offering

Core Viewpoint - Moleculin Biotech, Inc. has announced a public offering of 16,080,000 shares of common stock and Series E warrants, priced at $0.37 per share, aiming to raise approximately $5.9 million to advance its drug development pipeline [1][2]. Group 1: Offering Details - The public offering includes 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares, with a combined offering price of $0.37 per share [1]. - The offering is expected to close on or about June 23, 2025, subject to customary closing conditions [2]. - Gross proceeds from the offering are anticipated to be approximately $5.9 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the development of Annamycin and two other drug portfolios through clinical development [2]. - Funds will also support preclinical studies and research sponsorship, as well as working capital needs [2]. Group 3: Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses, with its lead program Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma [6][7]. - The company is conducting the MIRACLE trial, a pivotal Phase 3 study evaluating Annamycin in combination with cytarabine for AML treatment [7]. - Additionally, Moleculin is developing WP1066, an immune/transcription modulator for various cancers, and a portfolio of antimetabolites including WP1122 for treating pathogenic viruses [8].